Enhancing cardiovascular risk prediction in hypertensive adults: a 3PM-based evaluation of insulin resistance and

Yulong Lan1,2, Zhaogui Wu3, Dan Wu1,2

  • 1Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong China.

The EPMA Journal
|November 28, 2025
PubMed

Insights

Insulin resistance (IR) and arterial stiffness synergistically increase atherosclerotic cardiovascular disease (ASCVD) risk in hypertension patients. Combining these biomarkers improves risk prediction and enables personalized preventive strategies.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Syndrome
  • Hypertension Research

Background:

  • Hypertension management is complicated by coexisting insulin resistance (IR) and arterial stiffness.
  • These conditions are silent, synergistic drivers of atherosclerotic cardiovascular disease (ASCVD).
  • Understanding their combined impact is crucial for effective ASCVD risk stratification.

Purpose of the Study:

  • To evaluate the joint impact of IR and arterial stiffness on ASCVD risk in hypertensive adults.
  • To assess the utility of these biomarkers in predictive, preventive, and personalized medicine (PPPM) strategies.

Main Methods:

  • Prospective cohort study of 30,094 hypertensive adults.
  • Insulin resistance assessed via triglyceride-glucose (TyG) index.
  • Arterial stiffness measured by brachial-ankle pulse wave velocity (baPWV).
  • Time-to-event analyses for ASCVD incidence.

Main Results:

  • A median 5.6-year follow-up observed 1655 ASCVD cases.
  • Elevated TyG index showed a dose-response relationship with ASCVD risk across baPWV strata.
  • Individuals with both elevated TyG and baPWV had significantly higher ASCVD risk (HR: 1.93, 95% CI: 1.66-2.25).
  • A significant additive interaction (33.4% of joint risk) was identified.
  • Combined biomarkers improved model discrimination (C-index: 0.68) and reclassification (NRI: 18.63%).

Conclusions:

  • Insulin resistance and arterial stiffness have a synergistic effect on ASCVD risk.
  • Integrating these biomarkers into predictive models enhances early identification of high-risk hypertensive patients.
  • This dual-biomarker approach supports PPPM for optimizing cardiovascular outcomes through tailored interventions.
Abstract

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
443
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
226
Assessment of blood pressure in brachial artery(two-step method)01:23

Assessment of blood pressure in brachial artery(two-step method)

Measuring blood pressure is a fundamental skill in healthcare that aids in diagnosing and monitoring hypertension and other cardiovascular conditions. An aneroid sphygmomanometer, commonly used in clinical settings, offers a manual and precise method for blood pressure measurement. The technique for using this instrument involves specific steps that must be carefully executed to ensure accuracy. The following detailed description outlines a two-step technique for assessing blood pressure using...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
326
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
850